Skip to main content

Advertisement

Table 2 Response and Survival

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Docetaxel/Oxaliplatin (n = 44)
Efficacy Number of Patients Percent
Response
 Complete response (CR) 0  
 Partial response (PR) 7 15.9
 Stable disease (SD) 14 31.8
 Progressive disease (PD) 23 52.3
 Disease control rate (CR + PR + SD) 21 47.7
Survival months 95 % CI
 Median progression free survival 1.82 1.5–3.96
 Median overall survival 10.1 5.1–14.1
  1. 95 % CI confidence interval